MAZE Stock Summary and Trading Ideas (Maze Therapeutics | NASDAQ:MAZE)

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Maze Therapeutics trades on the NASDAQ stock market under the symbol MAZE.

As of April 14, 2026, MAZE stock price climbed to $27.68 with 2,340,701 million shares trading.

MAZE has a beta of 1.06, meaning it tends to be more sensitive to market movements. MAZE has a correlation of 0.02 to the broad based SPY ETF.

MAZE has a market cap of $1.33 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that MAZE belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

MAZE has outperformed the market in the last year with a return of +253.5%, while the SPY ETF gained +31.4%. However, in the most recent history, MAZE shares have underperformed the stock market with its stock returning -33.1% in the last 3 month period and -4.6% for the last 2 week period, while SPY has returned +0.4% and +9.9%, respectively.

MAZE support price is $26.29 and resistance is $28.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MAZE shares will trade within this expected range on the day.